Quetiapine (Seroquel) Dosing for Bipolar Disorder
For bipolar mania in adults, start quetiapine at 50 mg twice daily and titrate rapidly to a target dose of 400-800 mg/day; for bipolar depression in adults, start at 50 mg once daily at bedtime and titrate to 300 mg/day. 1
Acute Mania Dosing
Adults
- Initial dose: 50 mg twice daily (Day 1)
- Titration schedule: Increase by 100 mg/day to reach 400 mg/day by Day 4, then adjust to 600 mg/day on Day 5, and up to 800 mg/day thereafter 1, 2
- Target dose: 400-800 mg/day (mean effective dose among responders is approximately 600 mg/day) 2
- Maximum dose: 800 mg/day 1
The evidence shows that 92% of patients reach 400 mg/day by Day 4 with this rapid titration schedule, which is generally well tolerated and produces statistically significant improvement in manic symptoms starting at Day 4 3, 2. The mean last-week dose among responders was 575-598 mg/day, with most responders receiving doses within the 400-800 mg/day range 2.
Children and Adolescents (10-17 years)
- Initial dose: 25 mg twice daily
- Target dose: 400-600 mg/day
- Maximum dose: 600 mg/day 1
Bipolar Depression Dosing
Adults
- Initial dose: 50 mg once daily at bedtime (Day 1)
- Titration: Increase to 100 mg on Day 2,200 mg on Day 3, and 300 mg on Day 4
- Target/Maximum dose: 300 mg/day 1
Both 300 mg/day and 600 mg/day doses demonstrated efficacy for bipolar depression, with no significant difference in outcomes between the two doses 4, 5. However, the FDA-approved maximum for bipolar depression is 300 mg/day, which provides an optimal balance of efficacy and tolerability 1.
Response rates for bipolar depression: 57.6-58.2% with quetiapine versus 36.1% with placebo; remission rates were 52.9% versus 28.4% 5. Improvement begins as early as Week 1 and is sustained through Week 8 4.
Special Populations
Elderly Patients
- Initial dose: 50 mg/day (lower than standard)
- Use slower titration and careful monitoring during initial dosing 1
Hepatic Impairment
- Initial dose: 25 mg/day
- Use slower titration as needed 1
Maintenance Therapy
For patients who respond to acute treatment, continue the same dose used during the acute phase. Quetiapine has demonstrated efficacy in preventing mood episode recurrence when continued as maintenance therapy, with doses typically in the 400-800 mg/day range for mania and 300 mg/day for depression 6.
Key Clinical Considerations
Quetiapine is FDA-approved for acute mania in adults and is recommended as a first-line treatment by CANMAT/ISBD guidelines 7, 8. While quetiapine is approved for acute mania in adults, it is commonly used off-label for bipolar depression based on strong evidence 7, 6.
Common adverse effects include dry mouth, sedation, somnolence, dizziness, and constipation, which are generally mild to moderate 3, 5. Monitor for metabolic changes including weight gain, hyperglycemia, and dyslipidemia throughout treatment 1.
Critical safety note: The rapid titration schedule to 400 mg/day by Day 4 is both evidence-based and well-tolerated, allowing for faster symptom control in acute mania 2. Do not delay reaching therapeutic doses unnecessarily, as early response (by Day 4) is associated with this dosing strategy 3.